Amylyx Pharma to remove ALS drug from US, Canada markets

Amylyx Pharmaceuticals NASDAQ:AMLX will withdraw its amyotrophic lateral sclerosis (ALS) drug – its only product in the market – from the U.S. and Canada after the treatment failed in a key late-stage trial.The drugmaker on Thursday also announced a 70% reduction in its workforce. It had 384 full…